Celon Pharma SA (CLN) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.101x

Based on the latest financial reports, Celon Pharma SA (CLN) has a cash flow conversion efficiency ratio of 0.101x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł36.63 Million ≈ $10.08 Million USD) by net assets (zł363.25 Million ≈ $99.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Celon Pharma SA - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Celon Pharma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Celon Pharma SA debt and liabilities for a breakdown of total debt and financial obligations.

Celon Pharma SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Celon Pharma SA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Tigo Energy Inc. NASDAQ:TYGO	-0.227x
SFC Energy AG XETRA:F3C	0.054x
Tien Phong Securities Corp VN:ORS	-0.314x
Byggmax Group AB ST:BMAX	-0.008x
Neumora Therapeutics, Inc. NASDAQ:NMRA	-0.353x
Kosy JSC VN:KOS	-0.036x
Anhui Chaoyue Environmental Protection Technology Co. Ltd. SHE:301049	N/A
Forward Air Corporation NASDAQ:FWRD	0.374x

Annual Cash Flow Conversion Efficiency for Celon Pharma SA (2012–2025)

The table below shows the annual cash flow conversion efficiency of Celon Pharma SA from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Celon Pharma SA (CLN) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	zł363.25 Million ≈ $99.97 Million	zł23.85 Million ≈ $6.56 Million	0.066x	+357.83%
2024-12-31	zł445.21 Million ≈ $122.53 Million	zł-11.34 Million ≈ $-3.12 Million	-0.025x	-36.49%
2023-12-31	zł445.56 Million ≈ $122.62 Million	zł-8.31 Million ≈ $-2.29 Million	-0.019x	-90.39%
2022-12-31	zł479.65 Million ≈ $132.01 Million	zł-4.70 Million ≈ $-1.29 Million	-0.010x	-112.35%
2021-12-31	zł554.00 Million ≈ $152.47 Million	zł43.95 Million ≈ $12.10 Million	0.079x	-51.36%
2020-12-31	zł434.67 Million ≈ $119.63 Million	zł70.90 Million ≈ $19.51 Million	0.163x	+1537.33%
2019-12-31	zł445.04 Million ≈ $122.48 Million	zł-5.05 Million ≈ $-1.39 Million	-0.011x	-118.03%
2018-12-31	zł448.73 Million ≈ $123.50 Million	zł28.24 Million ≈ $7.77 Million	0.063x	+9.40%
2017-12-31	zł439.85 Million ≈ $121.05 Million	zł25.30 Million ≈ $6.96 Million	0.058x	+12.15%
2016-12-31	zł402.50 Million ≈ $110.77 Million	zł20.65 Million ≈ $5.68 Million	0.051x	-90.13%
2015-12-31	zł100.82 Million ≈ $27.75 Million	zł52.37 Million ≈ $14.41 Million	0.519x	+48.46%
2014-12-31	zł69.62 Million ≈ $19.16 Million	zł24.36 Million ≈ $6.70 Million	0.350x	+116.14%
2013-12-31	zł52.20 Million ≈ $14.37 Million	zł8.45 Million ≈ $2.33 Million	0.162x	-30.09%
2012-12-31	zł55.57 Million ≈ $15.29 Million	zł12.87 Million ≈ $3.54 Million	0.232x	--

About Celon Pharma SA

WAR:CLN Poland Drug Manufacturers - Specialty & Generic

Market Cap

$312.75 Million

zł1.14 Billion PLN

Market Cap Rank

#14854 Global

#87 in Poland

Share Price

zł21.10

Change (1 day)

+0.96%

52-Week Range

zł18.82 - zł24.10

All Time High

zł51.09